Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Warp Drive Bio (Cambridge, MA) a development-stage biopharma company focused on a proprietary genomic search engine to identify and develop natural product drug candidates in microbes to target previously undruggable targests, closed a $75M Series A financing. Participants include Third Rock Ventures, Greylock Partners and Sanofi.

RaNA Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on platform that allows selective gene activation and therapeutic factor expression by targeting long, noncoding RNA, closed a $20.7M Series A financing. Participants include Monsanto, SR One and Atlas Venture.

Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.

Selecta Biosciences (Watertown, MA) a clinical-stage biopharmaceutical company focused on a new class of vaccines and immunotherapies for nicotine addiction, cancer, diabetes, influenza and human papilloma virus (HPV) closed a $47.25M Series D financing. Participants include Rusnano.

Bind Biosciences (Cambridge, MA) a clinical-stage biopharmaceutical company focused on new class of highly selective targeted chemotherapeutic nano-therapeutics for solid tumors, closed a $25.5M Series D financing. Participants include Rusnano.

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Esperance Pharmaceuticals (Baton Rouge, LA) a clinical-stage oncology and companion diagnostic company, closed a $7.5M Series B financing. Participants include Sanofi, Louisiana Fund, Themelios Ventures, Research Corporation Technologies and Advantage Capital Partners.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Covagen (Switzerland) a development-stage biopharmaceutical company focused on a protein scaffold platform (Fynomer) for therapeutic use, closed a $6.5M Series A financing. Participants include Seroba Kernel Life Sciences, Edmond de Rothschild Investment Partners, MP Healthcare Venture Management, Novartis Venture Fund and Ventech.

« Previous Entries  Next Page »

to top of page...